ABSTRACT
BACKGROUNDS: Restless legs syndrome (RLS) is an unpleasant condition that affects the quality of life of patients. Its prevalence in increased in women with premenstrual syndrome (PMS). Vitamin D plays a key role in female reproduction through its impact on calcium homeostasis and neurotransmitters. We aimed to evaluate the effect of dairy products fortified with Vitamin D3 on RLS in women with PMS. MATERIALS AND METHODS: We conducted a 2.5-month, randomized, total-blinded clinical trial to evaluate the effectiveness of low-fat milk and yogurt fortified with vitamin D on RLS in women with PMS. Among 141 middle-aged women with abdominal obesity, 71 and 70 cases received fortified and non-fortified low-fat dairy products, respectively. All subjects completed a Symptoms Screening Tool (PSST) and RLS questionnaires. RESULTS: The results showed that in the women with severe PMS (PSST > 28), serum levels of vitamin D increased significantly following vitamin D fortification. The mean restless legs score in the severe PMS subgroup (PSST > 28) was significantly lower after the intervention (p < 0.05. Serum Vitamin D levels significantly differed between intervention and control groups in all individuals (PSST < 19, PSST 19-28, and PSST > 28) (p < 0.05), but no significant differences were found between RLS scores of the intervention and control groups in the three PMS subgroups (p > 0.05). CONCLUSION: Fortifying dairy products with vitamin D3 can increase the serum levels of vitamin D and reduce the RLS severity in women with severe PMS, but not in other groups.
Subject(s)
Cholecalciferol , Dairy Products , Food, Fortified , Obesity, Abdominal , Premenstrual Syndrome , Restless Legs Syndrome , Vitamin D Deficiency , Adult , Female , Humans , Middle Aged , Cholecalciferol/therapeutic use , Cholecalciferol/administration & dosage , Obesity, Abdominal/complications , Obesity, Abdominal/diet therapy , Pilot Projects , Premenstrual Syndrome/drug therapy , Premenstrual Syndrome/diet therapy , Restless Legs Syndrome/drug therapy , Restless Legs Syndrome/blood , Restless Legs Syndrome/etiology , Vitamin D Deficiency/complications , Vitamin D Deficiency/drug therapyABSTRACT
Contamination of food and water with radioactive substances is a serious health problem. There are several methods to detect and measure radioactive materials, some of which have been developed in recent years. This paper aims to discuss the methods of detecting and measuring radioactive substances in food and water. The principles and the advantages and disadvantages of each method have been discussed. The results showed that some of these methods, such as spectrometry γ-ray high-purity germanium, portable radon gas surveyor SILENA, RAD7, and inductively coupled plasma mass spectrometry, have a higher sensitivity for detection and measurement. The spectrometry γ-ray high-purity germanium method has attracted more attention than other methods because it can measure a wide range of radionuclides with high resolution.
ABSTRACT
INTRODUCTION: Vitamin D deficiency has been reported to affect liver function biomarkers. This study was aimed to investigate the effect of consuming vitamin D fortified low-fat dairy products on liver function tests in adults with abdominal obesity. METHODS: This total blinded randomized controlled trial was undertaken on otherwise healthy abdominally obese adults living in Mashhad, Iran. Milk and yogurt were fortified with 1500 IU vitamin D3 nano-capsules. Participants were randomized to receive fortified milk (n = 73), plain milk (n = 73), fortified yogurt (n = 69), and plain yogurt (n = 74) for 10 weeks. Blood samples were taken at baseline and at the end of the study to assess serum levels of vitamin D, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase (ALP), and Gamma glutamyl transferase. RESULTS: A total of 289 participants completed the study (54% female). The groups were homogenous in terms of age, sex, weight, energy intake, and physical activity level (p-value > 0.05). After the trial, vitamin D serum levels were significantly increased in both groups receiving fortified products (both p < 0.001). There was a significant time*group effect only in serum ALP (p < 0.001). CONCLUSION: Consumption of dairy products fortified by 1500 IU vitamin D3 might have detrimental effects on serum levels of some liver enzymes in individuals with abdominal obesity. Further studies needed to determine these effects and underlying mechanisms. TRIAL REGISTRATION: IRCT20101130005280N27 .
Subject(s)
Cholecalciferol , Obesity, Abdominal , Adult , Female , Humans , Male , Animals , Obesity, Abdominal/complications , Cholecalciferol/therapeutic use , Obesity , Milk , Vitamin D , Biomarkers , LiverABSTRACT
BACKGROUND: Due to the benefits of blenderized tube feeding (BTF) diets, the interest in using them is increasing. This study aimed to design BTFs for children and investigate their physicochemical and microbial properties, as well as Dietary Inflammatory Index (DII). METHODS: Five BTF diets were formulated mainly with fresh foods; their DII, physical (viscosity), and chemical (moisture, ash, protein, fat, energy, and micronutrients) characteristics were assessed. Also, the Hazard Analysis and Critical Control Points (HACCP) system was implemented for quality assurance of preparation, storage, and delivery of BTFs to patients in hospital. The microbial contamination (total count, Salmonella, Escherichia coli, Bacillus cereus, Listeria monocytogenes, coliforms, Staphylococcus aureus coagulase positive, mold, and yeast) was analyzed. RESULTS: Energy and percentages of protein, fat, and carbohydrate in BTFs were in the range of 103-112 kcal/100 ml, 16%-22%, 28%-34%, and 48%-52%, respectively. The viscosity of the five developed BTFs was between 29 and 64 centipoises, which allows the formulas to flow without syringe pressure. The DII of all BTFs was between -0.73 and -2.24. Due to the implementation of HACCP, monitoring the production line of BTFs, and performance of corrective measures, no microbial contamination was observed by indicator pathogenic microorganisms. CONCLUSION: A planned BTF diet can be an excellent selection for children using enteral nutrition with tube feeding especially when they are made from fresh and anti-inflammatory foods such as recipes prepared in this study.
Subject(s)
Enteral Nutrition , Food, Formulated , Humans , Child , Food, Formulated/analysis , Diet , Micronutrients , Escherichia coliABSTRACT
BACKGROUND: The prevalence of vitamin D deficiency is increasing globally and is associated with an increased risk of metabolic syndrome, autoimmune disease, and cardiovascular disease. Vit D deficiency is also associated with increased systemic inflammation. The current study aimed to determine the efficacy of low-fat milk and yogurt fortified with 1500 IU nano-encapsulated vitamin D, on systemic inflammation in abdominal obese participants. METHOD: This multi-center study was conducted using a 2.5-month parallel total-blind randomized clinical trial design. Two hundred and eighty nine subjects were allocated to four groups: low-fat milk fortified by 1500 IU nano-encapsulated vitamin D3 (200 mL/day). Simple milk (200 mL/day), low-fat yogurt fortified by 1500 IU nano-encapsulated vitamin D3 (150 g/day), and simple yogurt (150 g/day). RESULTS: The results showed that serum levels of neutrophils, lymphocytes, platelets and red blood cell distribution width (RDW) were significantly lower before and after the intervention in fortified dairy groups. The results showed that serum levels of neutrophils, lymphocytes, platelets, and RDW before and after intervention in the fortified dairy groups were significantly lower (p < 0.05). The values of = neutrophil to lymphocyte ratio (NLR), platelets to lymphocyte ratio, and RDW to platelets ratio (RPR) reduced significantly in the fortification group (p < 0.05). CONCLUSION: Fortification with nano-encapsulated vitamin D3 of dairy products may decrease inflammation in individuals with abdominal obesity.
Subject(s)
Cholecalciferol , Vitamin D Deficiency , Adult , Animals , Cholecalciferol/therapeutic use , Food, Fortified , Humans , Inflammation , Milk , Obesity, Abdominal/complications , Vitamin D , Vitamin D Deficiency/complications , YogurtABSTRACT
Vitamin D is an essential vitamin for bone marrow development and immune function, which is mostly synthesized in the skin through sun exposure. The high global prevalence of vitamin D deficiency requires a feasible approach to administer vitamin D to a larger number of population in a shorter amount of time, and this may be achieved through food fortification. Food fortification using nanostructured lipid carriers (NLC) and nanoemulsions appears to be an ideal method to enhance bioavailability, stability, and solubility of bioactive compounds. The aim of this study was to develop NLC and nanoemulsion forms of vitamin D to evaluate its efficacy for further enrichment of dairy products. NLC containing Precirol and nanoemulsion containing vegetable oils were prepared and characterized for polydispersity index, particle size, zeta potential, particle shape, crystal properties, stability, encapsulation efficiency, and releasing. Vitamin D3 NLC size was in the range of 123.4 to 210.6 nm and for nanoemulsion 137.6 to 171.6 nm, respectively. Optimal NLC and nanoemulsion carriers were selected for morphological assessment, encapsulation efficiency, thermal analysis, and release study. Scanning and transmission electron microscopy revealed that particles had approximately spherical shape. In gastric simulated solution (pH = 1.2), NLC and nanoemulsion form of vitamin D3 released 9.3% and 26.9% of vitaminD3, respectively. This indicated that our formulation is able to protect vitamin D3 under acidic conditions. The results of this study revealed that NLC and nanoemulsion could be an optimal carrier for food fortification in order to improve bioavailability of bioactive compounds such as vitamin D.
Subject(s)
NanostructuresABSTRACT
BACKGROUND AND AIM: The current study aimed to assess the effect of fortified yogurt with nano-encapsulated vitamin D on serum pro-oxidant anti-oxidant balance (PAB) in adults with or without metabolic syndrome. METHODS: In a quadruple blind clinical trial study, 139 adults with an age range of 30-50 years were randomly selected to receive either 1500 IU nano-encapsulated vitamin D fortified yogurt or placebo for ten weeks. Before and after the intervention period, blood sample was taken to determine the serum levels of vitamin D, pro-oxidant-antioxidant balance (PAB), and high-sensitivity C-reactive protein (hs-CRP). The laboratory tests were checked at baseline and at the end of the treatment. RESULTS: Serum vitamin D increased significantly, from 14.47 ± 6.07 ng/mL to 21.39 ± 6.54 ng/mL (P < 0.001) after ten weeks in the intervention group. Serum hs-CRP and PAB were significantly lower following consumption period in intervention group [1.95(0.4-8.15) g/dL vs. 1.35(0.25-3.62) g/dL; P = 0.013] and (135.19 ± 42.4 HK vs. 115.39 ± 44.69) HK; P = 0.018] respectively. There were no significant differences between the intervention and control groups regarding weight and BMI at the end of the intervention period (p > 0.05). CONCLUSION: Low-fat yogurt fortified with nano-encapsulated vitamin D was found to reduce serum PAB levels in adults with metabolic syndrome. PRACTICAL APPLICATION: The findings of the present study indicated that a low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D for ten weeks, leads to a significant reduction in serum hs-CRP and PAB concentrations highlighted the anti-inflammatory/anti-oxidative effect of vitamin D.
Subject(s)
Antioxidants/metabolism , Metabolic Syndrome/blood , Nanocapsules/administration & dosage , Oxidants/blood , Vitamin D/administration & dosage , Yogurt , Adult , Diet, Fat-Restricted/methods , Double-Blind Method , Female , Follow-Up Studies , Food, Fortified , Humans , Male , Metabolic Syndrome/diet therapy , Middle Aged , Reactive Oxygen Species/blood , Treatment OutcomeABSTRACT
BACKGROUND & AIMS: Vitamin D deficiency is widespread worldwide. In this study, we aimed to evaluate the effect of a nano encapsulated form of vitamin D used for fortifying low-fat dairy products (milk and yogurt) on anthropometric indices, glycemic status, and lipid profile in subjects with abdominal obesity. METHODS: In a totally (quadruple) blinded, randomized, and parallel-controlled trial, 306 individuals with abdominal obesity were randomly allocated to one of four groups: fortified low-fat yogurt (FY, 1500 IU nano encapsulated vitamin D3 per 150 g/d), non-fortified low-fat yogurt (nFY), fortified low-fat milk (FM, 1500 IU nano encapsulated vitamin D3 per 200 g/d), non-fortified low-fat milk (nFM), for 10 weeks (nFM and nFY, were considered as the control groups). Anthropometric and biochemical parameters were measured at baseline and after a ten-week trial in Mashhad, Iran. RESULTS: After the ten-week intervention, we found a significant increase in serum concentration of 25(OH)D in both the FM and FY groups compared to the respective control groups (19.10 ± 5.69 ng/mL and 20.88 ± 5.76 ng/mL respectively, p < .001). We observed a significant reduction in weight to hip ratio (p = .04) and a significant improvement in triglyceride (p < .001) and HDL-C (p = .01) only in FM group compared to nFM group. Also, we found a significant reduction in fasting serum insulin (p < .001), and a significant improvement of HOMA-IR (p < .001) and QUICKI (p < .001) in both intervention groups compared to their placebos. CONCLUSIONS: An intake of fortified dairy products containing nano-encapsulated vitamin D3 was associated with an improvement in some measures of anthropometric indices, glucose homeostasis, and lipid profiles, particularly in individuals receiving fortified milk. Hence, along with other benefits, fortification of dairy products with vitamin D may be an effective approach to improve some cardiometabolic indicators, such as insulin resistance. TRIAL REGISTRATION NUMBER: IRCT20101130005280N27.
Subject(s)
Cardiovascular Diseases , Obesity, Abdominal , Adult , Cholecalciferol , Dairy Products , Double-Blind Method , Food, Fortified , Humans , Obesity, Abdominal/drug therapy , Vitamin DABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti-inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two-dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41-22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (-0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high-sensitivity C-reactive protein (hs-CRP) levels compared with the placebo group (-0.371; 95%CI: -0.582 to -0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups (p > .05). There was no significant improvement in insulin resistance in both groups (p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs-CRP in patients with NAFLD.
Subject(s)
Anti-Infective Agents/therapeutic use , Elasticity Imaging Techniques/methods , Fibrosis/metabolism , Non-alcoholic Fatty Liver Disease/drug therapy , Propolis/therapeutic use , Anti-Infective Agents/pharmacology , Female , Humans , Male , Propolis/pharmacology , TransfectionABSTRACT
INTRODUCTION: Sleep disorders are a common condition globally. Vitamin D receptors are present on cells in several regions of the brain. It is possible that vitamin D status may affect brain function, including sleep patterns. We aimed to evaluate the 1,500 IU of Nano-encapsulated vitamin D fortified in dairy products on the symptoms of insomnia and associated improvement of quality of life. METHODS: A case series was undertaken as part of the Survey of ultraviolent intake by nutritional approach project. Subjects enrolled among adults with abdominal obesity. Twenty-nine subjects with insomnia were selected according to the results of Insomnia Severity Index questionnaire and quality of life using a Short Form Health Survey (SF-36) questionnaire. Subjects were allocated to four groups: low-fat milk fortified by 1,500 IU vitamin D3 (n = 8), simple milk (n = 8), low-fat yogurt fortified by 1,500 IU vitamin D3 (n = 7), and simple yogurt (n = 6) and were treated for 10 weeks. RESULTS: The insomnia score improved after the intervention in the group receiving vitamin D fortified milk compared to group receiving unfortified milk (p < .001). There were no significant differences between the two groups taking yogurt (fortified vs. unfortified). Comparison of quality of life scores between baseline and after intervention indicated significant improvements in both fortified and simple milk groups (p = .002 and p = .03, respectively); but no differences were found in the groups taking yogurt. CONCLUSION: Fortified low-fat milk containing 1,500 IU vitamin D3 can improve insomnia symptoms and subsequently quality of life.Trial registration number: IRCT20101130005280N27, www.IRCT.ir.
ABSTRACT
From an interfacial phenomena standpoint, gallic acid (GA), methyl gallate (MG), and their combination alone and together with lecithin (L) were evaluated for their inhibition against the formation of lipid hydroperoxides and carbonyl compounds in a stripped sunflower oil. Lecithin at a level (500 ppm) lower than its critical micelle concentration was able to protect the lipid system to some extent. GA (log P = -0.21), which was of higher capacity than MG (log P = - 0.14) in donating H/e- (IC50 = 36.4 vs. 39.9 µM and FRAP value = 598 vs. 514 µmol/L, respectively), exerted an antioxidant activity significantly better than MG in the bulk phase oil. Due to the improved interfacial performance, the inhibitory effect of the antioxidants was remarkably promoted in the presence of lecithin (L/GA/MG > L/GA > L/MG).
Subject(s)
Antioxidants/chemistry , Gallic Acid/analogs & derivatives , Gallic Acid/chemistry , Lecithins/chemistry , Lipid Peroxidation , Sunflower Oil/chemistry , Lipid Peroxides/chemistry , Lipids/chemistryABSTRACT
Antioxidant activity of the natural flavonoids luteolin and catechin, which shows inconsistent comparative results in literature, was extensively evaluated as affected by the 1,4-pyrone moiety and 3-OH group. Catechin and luteolin were compared to the synthetic antioxidant-butylated hydroxytoluene for their 2,2-diphenyl-1-picrylhydrazyl (DPPHâ ) scavenging activity in polar protic and aprotic solvents and ferric reducing-antioxidant power (FRAP). Moreover, their effect on lipid oxidation kinetics of canola and olive oil triacylglycerols as well as their oil-in-water (O/W) emulsions, in addition to oil stability indices (OSIs), was evaluated. In the DPPHâ assay, catechin's 3-OH group led to lower IC50 values than luteolin's 1,4-pyrone moiety in acetone (3.4 µM compared with 9.4 µM), while there was no significant difference in methanol (IC50 = approximately 18.3 µM) or tetrahydrofuran (IC50 = approximately 27.2 µM). The FRAP test indicated a higher reducing power for catechin than for luteolin (689.4 µM compared with 573.1 µM). The antioxidants showed various performances in the oil triacylglycerols and their O/W emulsions due predominantly to the interfacial phenomena. A better OSI was found for catechin than for luteolin (20.0 to 52.7 hr compared with 3.5 to 4.2 hr) in Rancimat test.
Subject(s)
Antioxidants/chemistry , Catechin/chemistry , Luteolin/chemistry , Antioxidants/pharmacology , Catechin/pharmacology , Kinetics , Luteolin/pharmacology , Oxidation-Reduction , Structure-Activity RelationshipABSTRACT
Basal cell carcinoma is a common non-melanotic skin cancer with a prevalence of 74.5%-82.6% in the Iranian population. BCC rarely metastasizes. However, metastasis can cause significant morbidity. The prevalence of metastatic basal cell carcinoma varies between 0.0028% and 0.55% of all cases. We describe a case of lung metastasis of basal cell carcinoma of the scalp.
ABSTRACT
OBJECTIVES: In food industry, the inhibition of tyrosinase is very important, because this enzyme catalyzes the oxidation of phenolic compounds found in fruits and vegetables into quinones, which contribute in undesirable color and taste of fruits and vegetables. Teucrium polium L. var. gnaphalodes (Lamiaceae), a wild-growing flowering plant that has many applications in food preparations and traditional medicine. In Persian language, this medicinal herb is called Kalpoureh. MATERIALS AND METHODS: 1D- and 2D-NMR experiments were used to determine the chemical structures of the isolated compounds. Antioxidant and tyrosinase inhibitory activities of the isolated compounds were evaluated using DPPH, FRAP and mushroom tyrosinase inhibition assays. RESULTS: In this research, we isolated two phenylpropanoid glycosides including verbascoside and poliumoside and two flavonoids including jaranol and isorhoifolin using chromatographic techniques. We found promising antioxidant and anti-tyrosinase compounds from Teucrium polium L. var. gnaphalodes. CONCLUSION: To date, different compounds have been isolated and characterized from T. polium including terpenoids and flavonoids. But no phytochemical study has been reported from T. polium var. gnaphalodes. Poliumoside and jaranol showed promising antioxidant and tyrosinase inhibitory activities, respectively.
ABSTRACT
Pleuroscopy is a safe diagnostic procedure for evaluation of pleural diseases, with minimum complications. This procedure has been recently conducted on outpatient basis. Results support its safety, especially in busy referral hospitals. We aimed to report our experience on performing outpatient pleuroscopy at Masih Daneshvari hospital; Tehran, Iran. All eligible patients referred to Masih Daneshvari Hospital for pleuroscopy between May 2015 and May 2016 were enrolled. Air evacuation was conducted in operating room though a thin Nelaton catheter attached to low pressure suction. Compression dressing using Vaseline gauze was done after air leak terminated. Patients were discharged if first chest x-ray was negative for pneumothorax and were advised to stay in touch and return 12 hours later for second chest radiograph. Baseline characteristics, radiographic and pathologic reports were reviewed. Outpatient pleuroscopy was conducted on 10 patients. Average procedure time was 22±9 minutes. All patients were discharged after 4 hours. Eight of the patients remained free of complications after 12 hours, and 2 patients presented with pneumothorax (both who had massive pleural effusion) and were successfully managed by our team. Considering pathologic diagnosis, pleural tuberculosis was as common diagnosis as malignancy in our patients (4 patients), adenocarcinoma was the most malignancy reported (3 out of 4 patients). Chronic nonspecific inflammation was reported by our pathologist in 2 cases. Outpatient pleuroscopy can be conducted safely and effectively, reducing the number of unnecessary hospitalizations in a referral center. Closed follow up, patient education and proper patient selection are necessary for minimizing complications.
Subject(s)
Outpatients , Pleural Diseases/diagnosis , Referral and Consultation , Thoracoscopy , Adenocarcinoma/diagnosis , Adenocarcinoma/epidemiology , Adult , Cross-Sectional Studies , Female , Humans , Iran/epidemiology , Male , Mesothelioma/diagnosis , Mesothelioma/epidemiology , Middle Aged , Outpatients/statistics & numerical data , Patient Selection , Pleural Diseases/diagnostic imaging , Pleural Diseases/epidemiology , Pleural Effusion/diagnosis , Pleural Effusion/epidemiology , Pleural Neoplasms/diagnosis , Pleural Neoplasms/epidemiology , Predictive Value of Tests , Referral and Consultation/statistics & numerical data , Sensitivity and Specificity , Thoracoscopy/methodsABSTRACT
Bene is an edible fruit from the tree Pistacia atlantica subsp. mutica, and is of steadily growing interest in recent years due to its significant antioxidant properties and potential health benefits. An antioxidant activity-guided fractionation of the methanol extract from Bene hull together with an integrated approach of HPLC-DAD, LC-MS and (1)H NMR techniques led to the identification of main antioxidant phenolic compounds for the first time. Radical scavenging activity of each fraction/compound was tested using DPPH and FRAP assays. The phenolic content of the fractions was also determined by Folin-Ciocalteu's method. The main identified antioxidant compounds were luteolin (46.53% w/w of total extract), gallic acid (9.84% w/w), 2â³-O-galloylisoquercitrin (0.53% w/w), quercetin 3-rutinoside (0.34% w/w) and 2â³-O-cis-caffeoylquercitrin (0.26% w/w). The minor antioxidant compounds were also identified by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. The structure-antioxidant activity relationship of identified phenolics are also discussed in this paper.
Subject(s)
Antioxidants/analysis , Magnetic Resonance Spectroscopy/methods , Pistacia , Plant Extracts/analysis , Tandem Mass Spectrometry/methods , Antioxidants/chemistry , Chromatography, High Pressure Liquid/methods , Chromatography, Liquid/methods , Plant Extracts/chemistryABSTRACT
The tree Pistacia atlantica subsp. mutica, namely Bene, is widely distributed in Iranian mountains. Recent studies revealed that the oil of Bene was stable, even more stable than sesame oil, with antioxidant properties. This can give versatile applications for the oil. The volatile composition of this oil has not chemically been investigated so far. In this study, sixty three compounds were identified in the essential oil (EO) of Bene hull. The major components were determined to be α-pinene (20.8 %), camphene (8.4 %), ß-myrcene (8.2 %) and limonene (8 %). Antioxidant activities of the essential oil from Bene hull were evaluated by using 2,2'- diphenyl-1-picrylhydrazyl (DPPH) free radical-scavenging, ferric reducing antioxidant power (FRAP), ß-carotene bleaching test, thiobarbituric acid reactive species (TBARS) and Rancimat assays. The Bene essential oil exhibited significant antioxidant activities in FRAP and TBARS assays as compared with positive controls. In addition, the oil was evaluated for its antimicrobial activity against both Gram positive (Staphylococcus aureus) and Gram negative (Escherichia coli) bacteria. It showed significant antibacterial activities against S. aureus and E. coli with minimum inhibitory concentration (MIC) values of 6 and 12.5 µg/mL, respectively.
ABSTRACT
Extraction yield, phenolics content, and antioxidant activities of the materials extracted conventionally and/or ultrasonically from Bene hull by a number of aqueous and organic solvents were investigated. Higher extraction yields in general were obtained by the less polar solvents (12.1-47.5%). Polar protic solvents exhibited the highest content of total phenolics extracted (110-150 mg/g), followed by polar aprotic (30.0-43.5 mg/g) and non-polar solvents (3.3-5.2 mg/g). Good correlation (R(2)=0.9721) was obtained between the DPPH radical-scavenging activities and total phenolics contents. Many similarities were observed between the results of the DPPH (EC50=0.6-1105.3 µg/ml) and FRAP (0.1-8.5 mmol/g) assays. The highest oxidative stability index (OSI) value belonged to the methanol and water extracts, respectively. All the extraction factors significantly improved by 30 min sonication, especially in polar protic solvents. A 10-min sonication in water extraction could provide the same achievements as those of the 24-h conventional method.
Subject(s)
Antioxidants/chemistry , Antioxidants/isolation & purification , Pistacia/chemistry , Seeds/chemistry , Solvents/chemistry , Antioxidants/pharmacology , Chemical Phenomena , Methanol , Oxidation-Reduction , Phenols/chemistry , Plant Extracts/chemistry , Ultrasonics , WaterABSTRACT
Complex molecular changes that occur during prostate cancer (PCa) progression have been described recently. Whole genome sequencing of primary PCa samples has identified recurrent gene deletions and rearrangements in PCa. Specifically, these molecular events disrupt the gene loci of phosphatase and tensin homolog (PTEN) and membrane-associated guanylate kinase inverted-2 (MAGI2). In the present study, we analyzed the expression profile of MAGI2 gene in a cohort of clinical PCa (n = 45) and benign prostatic hyperplasia (BPH) samples (n = 36) as well as three PCa cell lines. We also studied the expression of PCa-related genes, including PTEN, NKX3.1, SPINK1, DD3, AMACR, ERG, and TMPRSS2-ERG fusion in the same samples. The expression of MAGI2 mRNA was significantly down-regulated in PC3, LNCaP and DU-145 PCa cell lines (p = 0.000), and also in clinical tumor samples (Relative expression = 0.307, p = 0.002, [95 % CI 0.002-12.08]). The expression of PTEN, NKX3.1, SPINK1, DD3, and AMACR genes was significantly deregulated in prostate tumor samples (p range 0.000-0.044). A significant correlation was observed between MAGI2 and NKX3.1 expression in tumor samples (p = 0.006). Furthermore, the inclusion of MAGI2 in the gene panel improved the accuracy for discrimination between PCa and BPH samples with the sensitivity and specificity of 0.88 [CI 0.76-0.95] and 0.83 [CI 0.68-0.92], respectively. The data presented here suggest that MAGI2 gene can be considered as a novel component of gene signatures for the detection of PCa.
Subject(s)
Carrier Proteins/metabolism , Genetic Markers , Prostatic Neoplasms/genetics , Transcriptome , Adaptor Proteins, Signal Transducing , Aged , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Carrier Proteins/genetics , Cell Line, Tumor , Disease Progression , Down-Regulation , Gene Deletion , Gene Expression Regulation, Neoplastic , Guanylate Kinases , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Iran , Male , Membrane Proteins/genetics , Membrane Proteins/metabolism , Middle Aged , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism , Prostate/cytology , Prostate/pathology , Prostatic Hyperplasia/genetics , Racemases and Epimerases/genetics , Racemases and Epimerases/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Transcriptional Regulator ERG , Trypsin Inhibitor, Kazal PancreaticABSTRACT
Cytotoxic activity of gaillardin, a sesquiterpene lactone isolated from Inula oculus-christi L. (Asteraceae), was assessed in the human breast adenocarcinoma cell line MCF-7, human hepatocellular carcinoma cell line HepG-2, human non-small cell lung carcinoma cell line A-549, and human colon adenocarcinoma cell line HT-29, resulting in IC50 values of 6.37, 6.20, 4.76, and 1.81 microg/mL, respectively, in the microculture tetrazolium-formazan MTT assay. In vitro apoptosis-inducing properties of gaillardin were also evaluated in MCF-7 cells with the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. The results suggest gaillardin as a candidate for further studies in cancer therapy